Getting a diagnosis like cancer, ALS, or a rare genetic condition is hard enough. But then hearing that there are no approved treatments left? That can feel like a wall closing in. The good news is that the wall sometimes has a door. It is called expanded access, and more patients qualify for it than most people realize.
What Is Expanded Access, Anyway?
Expanded access is a legal pathway in the United States that lets patients use investigational drugs outside of a clinical trial. These are drugs still being tested. They have not yet been approved by the FDA. But when someone has a serious or life-threatening condition and no other treatment options remain, the FDA can allow access to these drugs.
It is also sometimes called compassionate use. The two terms are often used interchangeably, though “expanded access” is the official FDA term.
The process works like this. A doctor makes the request. The drug manufacturer has to agree to provide the drug. Then the FDA reviews and approves the request. In non-emergency cases, there is a statutory 30-day review window, though the FDA typically completes reviews within a few days. For emergencies, the FDA can give authorization by phone within hours.
Who Actually Manages These Programs?
Pharmaceutical companies often need help running these programs. Handling requests from hundreds of patients worldwide is complex. That is why services like Early Access Care exist. They work directly with pharmaceutical companies to manage the entire expanded access process, from reviewing incoming requests to coordinating with regulators globally. Their goal is to make the process faster and less burdensome so that more eligible patients can actually get the treatment they need.
This matters because delays in expanded access can be life-changing. For patients running out of time, every week counts.
The Big Misconception Most Patients Have
Many patients assume they need to be enrolled in a clinical trial to access investigational drugs. That is not true. Expanded access is a completely separate pathway. In fact, patients who do not qualify for a clinical trial often still qualify for expanded access. The eligibility criteria are typically broader.
There are three types of expanded access. Single patient access is for one person. Intermediate-size programs cover a small group of patients with similar needs. And treatment INDs or protocols cover larger groups, often in the later stages of a drug’s development.
The most common type is single patient access. A treating physician submits a request on the patient’s behalf. The FDA approves over 99% of single patient expanded access requests, which is far higher than most people expect.
How to Start the Conversation With Your Doctor
This is where many patients get stuck. They do not know how to bring it up, or they worry their doctor will brush it off.
Here are a few straightforward steps. First, ask your doctor directly if there are investigational drugs in development for your condition. Second, check ClinicalTrials.gov to find drugs currently being tested. Third, ask whether any of those drugs have an expanded access program. Some drug companies list their expanded access programs directly on the site.
It also helps to know that doctors can submit an emergency IND by phone if the situation is urgent. You do not have to wait for weeks of paperwork in an acute situation.
Understanding how preventive healthcare and early intervention connect to long-term outcomes is something the blog has covered thoroughly in its piece on preventive healthcare — and that mindset applies here too. Catching an option early, even one outside the standard care path, can make a real difference.
What About the Right to Try Act?
In 2018, the federal Right to Try Act created another pathway. It allows patients to access investigational drugs without going through the FDA first, as long as the drug has completed Phase 1 trials. However, the drug company still has to agree. And many patient advocates argue that the traditional expanded access route through the FDA offers better oversight and patient protections. Both pathways are worth asking your doctor about.
The Emotional Side Nobody Talks About
There is an emotional weight to all of this that often gets ignored. Researching expanded access while also managing a serious illness is exhausting. Patients and family members end up doing hours of research, often without medical training, just to understand what options exist.
That is worth naming. Because feeling overwhelmed by this process is completely normal. The best thing to do is lean on your care team, ask direct questions, and look for patient advocacy groups specific to your condition. Many of them have navigators who understand the expanded access process and can help you move through it faster.
For patients dealing with a serious or life-threatening illness, there are structured resources available that explain the compassionate use process clearly, including what to expect at each stage and what questions to ask your oncologist or specialist.
What to Do Right Now
If you or someone you love has run out of standard treatment options, here is what to do. Talk to your doctor this week. Ask specifically about expanded access. Search ClinicalTrials.gov for drugs in Phase 2 or Phase 3 for your condition. Contact the drug manufacturer directly if needed. And know that the FDA and the organizations working alongside pharmaceutical companies are largely on the patient’s side in these situations.
You do not have to accept that there are no options left. Sometimes the next option just has not been approved yet.
